Compare EARN & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EARN | BIOA |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.7M | 175.7M |
| IPO Year | 2013 | 2024 |
| Metric | EARN | BIOA |
|---|---|---|
| Price | $5.36 | $11.61 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | $5.88 | ★ $9.00 |
| AVG Volume (30 Days) | 292.9K | ★ 297.0K |
| Earning Date | 11-19-2025 | 11-06-2025 |
| Dividend Yield | ★ 17.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,893,000.00 | $5,917,000.00 |
| Revenue This Year | $8.43 | N/A |
| Revenue Next Year | $17.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 43.30 | N/A |
| 52 Week Low | $4.33 | $2.88 |
| 52 Week High | $6.99 | $20.37 |
| Indicator | EARN | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 54.26 | 78.27 |
| Support Level | $5.25 | $8.46 |
| Resistance Level | $5.55 | $9.62 |
| Average True Range (ATR) | 0.10 | 0.58 |
| MACD | 0.01 | 0.17 |
| Stochastic Oscillator | 59.57 | 97.30 |
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.